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PYRUVATE KINASE M2 (PKM2), A GLYCOLYTIC ENZYME, IS REQUIRED 
TO MAINTAIN VASCULAR BARRIER FUNCTION 
HARITA DHARANEESWARAN  
ABSTRACT 
RATIONALE - Metabolic enzymes, like pyruvate kinase M2 (PKM2), play an essential 
role in altering endothelial cell (EC) phenotypes and behavior. Extensive research has 
elucidated the function of PKM2, a rate-limiting glycolytic enzyme, in the context of 
cancer cells and in activated immune cells, but its role in EC biology is only newly 
emerging. Recent findings show PKM2 acts as a key regulator of angiogenesis. Where 
exogenous circulating PKM2 induces EC cell proliferation leading to increased tumor 
angiogenesis and growth. Also, PKM2 deficient ECs exhibit decreased proliferation and 
migration. The relevance of PKM2 in modulating vascular barrier function is yet to be 
defined. 
 
OBJECTIVE -This study attempts to elucidate the role of PKM2 in regulating vascular 
barrier function. 
 
METHODS AND RESULTS -  In vivo, EC specific deletion of PKM2 promotes 
increased vascular permeability in pulmonary capillary vessels and increased VEGF-
induced acute vessel permeability in mouse dermal vessels. Similarly, in vitro, PKM2 
deficient ECs exhibit decreased electrical resistance, disrupted VE-cadherin junctions and 
gap formations (illustrated via florescent VE-cadherin staining and phosphorylation of 
 vii 
VE- cadherin protein at tyrosine residue Y658). Mechanistically, the deletion of PKM2 in 
ECs leads to increased angiopoietin-2 (Ang-2) expression, a well-known modulator of 
vascular permeability. Also, deletion of Ang-2 was sufficient to attenuate vascular 
leakage in PKM2 deficient endothelium, indicating that vascular leaky phenotype 
observed in PKM2 deficient endothelium is mediated by increased Ang-2 expression.  
 
CONCLUSIONS -  PKM2, by modulating Ang-2 expression, plays a vital role in 
maintaining vascular barrier function.  
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TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES .............................................................................................................. x 
LIST OF FIGURES ........................................................................................................... xi 
LIST OF ABBREVIATIONS .......................................................................................... xiii 
INTRODUCTION .............................................................................................................. 1 
METHODS ....................................................................................................................... 12 
RESULTS ......................................................................................................................... 17 
DISCUSSION ................................................................................................................... 28 
APPENDIX ....................................................................................................................... 34 
LIST OF JOURNAL ABBREVIATIONS........................................................................ 38 
 ix 
REFERENCES ................................................................................................................. 39 
CURRICULUM VITAE ................................................................................................... 43 
 
  
 x 
LIST OF TABLES 
 
 
Table Title Page 
1 Forward and reverse primer sequences utilized for 
quantitative real-time polymerase chain reaction (qPCR) 
assay.   
 
14 
 
  
 xi 
LIST OF FIGURES 
Figure Title Page 
1 Figure 1: Diagram of PKM2 structure, function (nuclear and 
glycolytic) and regulation. 
10 
2 Figure 2: PKM1 and PKM2 subcellular localization in endothelial 
cells and Ang-2 mRNA expression in PKM2 deficient endothelium. 
11 
3 Figure 3: Endothelial-specific PKM2 knockout mice show 
increased basal pulmonary microvascular permeability. 
21 
4 Figure 4: Endothelial-specific PKM2 knockout mice are more 
sensitive to VEGF-induced vascular permeability 
22 
5 Figure 5: Loss of PKM2 expression results in decreased 
transendothelial electrical resistance (TEER). 
23 
6 Figure 6: Loss of PKM2 expression results in disrupted VE-
cadherin adherent junctions and gap formations. 
24 
7 Figure 7: PKM2 deficient endothelium induces VE-cadherin 
tyrosine phosphorylation at residues Y658. 
25 
 xii 
8 Figure 8: PKM2 deficient endothelium induces Ang-2 expression. 26 
9 Figure 9: Knockdown of Ang-2 in PKM2-defcient cells is sufficient 
to rescue decreased transendothelial electrical resistance (TEER). 
27 
 
10 Appendix A1: 1 hour after of reseeding, endogenous VE-cadherin 
expression localizes to the perinuclear region. 
34 
11 Appendix A2: 4 hours after of reseeding, VE-cadherin localizes at 
plasma membranes where cell-to-cell contacts occur. 
35 
12 Appendix A3: 24 hours after of reseeding, loss of PKM2 
expression results in disrupted VE-cadherin adherent junctions and 
gap formations. 
36 
13 Appendix A4: PKM2 deficient endothelium lack differential VE-
cadherin expression. 
37 
 
  
 xiii 
LIST OF ABBREVIATIONS 
Ang-1 ............................................................................................................ Angiopoietin 1 
Ang-2 ............................................................................................................ Angiopoietin 2 
EC ............................................................................................................... Endothelial Cell 
EBD..............................................................................................................Evans Blue Dye 
KO .......................................................................................................................... Knockout 
OX-PHOS ...................................................................................Oxidative Phosphorylation 
PBS ............................................................................................. Phosphate-Buffered Saline 
PBS-T ......................................................................... Phosphate-Buffered Saline/Tween 20 
PK ............................................................................................................... Pyruvate Kinase 
PKM1 .................................................................................................... Pyruvate Kinase M1 
PKM2 .................................................................................................... Pyruvate Kinase M2 
qPCR .................................................. Quantitative Real-Time Polymerase Chain Reaction 
TBS ....................................................................................................... Tris-Buffered Saline  
TBS-T ..................................................................................Tris-Buffered Saline/Tween 20 
VEGF .......................................................................... Vascular Endothelial Growth Factor 
 
 
 
 
 
 1 
INTRODUCTION 
 1. Introduction 
An emerging concept is that endothelial metabolism can affect endothelial cell (EC) 
phenotypes and behavior. Metabolic regulation of angiogenesis is an example of how EC 
metabolism can induce changes in EC phenotype and behavior (Verdegem et al., 2014). 
For instance, phosphofructokinase-2/fructose-2,6-bisphosphatase3 (PFKFB3), a rate-
limiting glycolytic metabolic enzyme was recently shown to drive sprouting, migration 
and proliferation of angiogenic ECs (De Bock et al., 2013; Stapor et al., 2014). This 
brings up the question of what role do other metabolic enzymes, like pyruvate kinase, 
play in altering EC phenotypes and behavior. This study attempts to investigate the role 
of pyruvate kinase, another rate-limiting glycolytic enzyme, in endothelial biology. 
Although extensive research has elucidated the function of PKM2 in context of cancer 
cells and in activated immune cells, little is known about PKM2 in endothelial cells.  
 
2. Pyruvate Kinase  
2.1 Pyruvate Kinase Isoforms 
Pyruvate Kinase is a rate-limiting glycolytic enzyme that irreversibly catalyzes 
phosphoenolpyruvate (PEP) and adenosine diphosphate (ADP) to pyruvate and adenosine 
triphosphate (ATP). In mammals, the PK family consists of four isozymes: PK liver 
(PKL), PK red blood cells (PKR), PK muscle 1 (PKM1), and muscle 2 (PKM2). The PK 
family of enzymes are encoded by two genes PKLR and PKM. (Israelsen and Vander 
Heiden, 2015, Dong et al., 2016; Alves-Filho and Pålsson-McDermott, 2016). 
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The four pyruvate kinase isozymes exhibit unique tissue expression and 
regulatory properties. All the isoenzymes have similar kinetic parameters with respect to 
ADP, but they differ in their kinetics with respect to PEP (Israelsen and Vander Heiden, 
2015).  
2.2 PKLR Gene, Expression and Regulation 
Under differential promoters, the PKLR gene encodes for: (1) PKL, enzyme 
found in liver, kidney, and intestine and (2) PKR, enzyme found in red blood cells. PKL 
has the lowest affinity to PEP and is under hormonal control. PKR is inhibited by 
glycolytic product ATP and thyroid hormone triiodo-l-thyronine (T3). Both PKL and 
PKR are activated by fructose-1,6-bisphophate (FBP), an earlier product of glycolysis 
(Israelsen and Vander Heiden, 2015, Dong et al., 2016; Alves-Filho and Pålsson-
McDermott, 2016). 
2.3 PKM Gene and Expression  
Through alternative splicing, the PKM gene encodes for both the M1 and M2 
isozymes (Israelsen and Vander Heiden, 2015). The inclusion of exon 9 generates the 
PKM1 isoenzyme. Expression of PKM2 isoenzyme requires both repression of exon 9 
through splicing factors PTB, hnRNPA1, and hnRNPA2 and inclusion of exon 10 
through splicing factor SRSF3 (Israelsen and Vander Heiden, 2015). Although PKM1 
and PKM2 have similar 3D structures, the isoform specific exons generate structural 
differences at the fructose-1,6-bisphophate (FBP) binding site and the dimer-dimer 
interface (Dong et al., 2016; Alves-Filho and Pålsson-McDermott, 2016). 
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The PKM1 form is a constitutively active isozyme that predominates in most 
terminally differentiated cell types and in cells with high catabolic demands (heart, 
muscle, brain). In contrast the PKM2 is the dominant isoform during development and in 
cells with more anabolic functions, such as regenerative tissue, cancer cells, and immortal 
cell lines (MCF10A). PKM2 is regulated by a variety of allosteric effectors (FBP) and 
post-translational modifications (Figure 1; Alves-Filho and Pålsson-McDermott, 2016). 
2.4 Regulation of PKM2 Activity. 
The PK enzyme is regulated by stabilizing and destabilizing its oligomeric 
configurations. The constitutively active PKM1 exists stably as a tetramer, allowing for 
optimal binding to substrate PEP. The stable tetramer form of PKM1 has higher PK 
activity than the dimeric or monomer forms. Unlike PKM1, PKM2 requires an activator 
to have high PK activity. In the presence of activators, PKM2 switches to a tetrameric 
form which exhibits high PK catalytic activity and is associated with catabolic 
metabolism. The high PK catalytic activity allows for conversion of PEP to pyruvate, 
which enter the TCA cycle to generate ATP via oxidative phosphorylation (OX-PHOS). 
In the absence of activators, PKM2 primarily exist as a dimeric or monomer with low PK 
activity, facilitating the formation and accumulation of glycolytic intermediates. These 
glycolytic intermediates are shuttled into the glycolysis branch pathways, such as 
glycerol synthesis and pentose phosphate pathway, to generate nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH) for ROS suppression and nucleotides for 
anabolic metabolism. 
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Various endogenous regulators (glycolytic metabolites, non-glycolytic metabolites, 
amino acids and small molecules) control the switching of PKM2 configuration and 
activity by affecting the binding affinity of substrate PEP to the active site on PKM2 
enzyme (Dong et al., 2016; Alves-Filho and Pålsson-McDermott, 2016). Fructose-1,6-
bisphophate (FBP), an upstream glycolytic intermediate, is an activator of PKM2. FBP 
binds allosterically to PKM2, promoting stabilization of PKM2 tetramer complex and 
increases its binding affinity to PEP (Christofk et al., 2008). PKM1 and PKM2 bound to 
FBP exhibit similar kinetic properties. Small molecules, DASA58 and TEPP46 are also 
allosteric activators of PKM2. Like FBP, these small molecules promote tetramer 
stabilization and increase PEP binding affinity (Vander Heiden et al., 2010). 
Additionally, amino acids like serine (Chaneton et al., 2012) and a de novo purine 
synthesis intermediate, succinylaminoimidazolecarboxamide ribose-5′ phosphate 
(SAICAR), can activate PKM2 activity (Keller et al., 2012; Keller et al., 2014). PKM2 
activity can be inhibited by the absence of allosteric activators or the presence of 
allosteric inhibitors. Some known allosteric inhibitors of PKM2 are amino acids 
(phenylalanine and alanine), thyroid hormone triiodo-l-thyronine (T3) or via tyrosine 
phosphorylation (Ashiwaza et al., 1991; (Uebelhoer and Arispe 2016). 
2.5 Non-glycolytic PKM2 Activity. 
Since the dimeric isoform of PKM2 can translocate to the nucleus, it also exhibits 
non-glycolytic functions. The nuclear PKM2 interacts with transcription factors (HIF-1α, 
STAT3, histone H3 and JMJD5) to induce genes required for proliferation and glycolysis 
(Figure 1; Alves-Filho and Pålsson-McDermott, 2016).  
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PKM2 can function as a transcriptional coactivator. Under hypoxic conditions, PKM2 
translocates to the nucleus and interacts with hypoxia-inducible factor (HIF)-1α to induce 
glucose metabolism in cancer cells (Luo et al., 2011). PKM2 gene transcription is also 
activated by HIF-1α, which in turn further promotes HIF-1α transactivation in a positive 
feedback look. PKM2 binds to Jumonji domain-containing protein 5 (JMJD5) and 
prevents PKM2 tetramerization. The JMJD5-PKM2 interaction induces PKM2 to be 
translocated into the nucleus and promotes HIF-1α mediated glucose metabolism in 
cancer cells (Wang et al., 2014). Nuclear PKM2 can also bind to phosphorylated β-
catenin Tyr 333, leading to β-catenin transactivation and epidermal growth factor 
receptor (EGFR)-promoted tumor proliferation (Yang et al., 2011; Lu, 2012). 
PKM2 can act as a protein kinase to phosphorylate substrates involved in 
proliferation and glycolysis. PKM2, using PEP as a phosphate donor, phosphorylates 
signal transducer and activator of transcription 3 (STAT3) at tyrosine-705 and histone 
H3 at threonine-11, promoting cancer progression (Gao et al., 2012). 
 
3. PKM2 and the Warburg Effect 
3.1 PKM2 and the Warburg Effect in cancer and immune cells 
Typically, most cells utilize oxidative phosphorylation (OX-PHOS) as an 
energetically more efficient method for generating large amounts of ATP (32-36 ATPs 
per glucose vs 2 ATPs per glucose during glycolysis). However, many cancer cells 
primarily are dependent on glycolysis to meet their bioenergetic needs, regardless of 
oxygen levels (Israelsen and Vander Heiden, 2015, Dong et al., 2016; Alves-Filho and 
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Pålsson-McDermott, 2016). This increased rates of aerobic glycolysis in cancer cells was 
termed the Warburg effect and is necessary for tumor growth. The Warburg effect is not 
exclusive to cancer cells but is also present in normal cells that are rapidly proliferating. 
(DONG 2016, Uebelhoer and Arispe 2016). Increased aerobic glycolysis has also been 
observed in proliferating lymphocytes (20-30 fold induction), activated macrophages, 
proliferating thymocytes, proliferating fibroblasts, and regenerating skeletal muscle cells.  
(Uebelhoer and Arispe 2016).  
In cancer cells, a prominent driver of the Warburg effect is PKM2. In fact, 
proliferating cancer cells switch from PKM1 to PKM2 to increase glycolysis for biomass 
production (Verdegem et al., 2014). Also, PKM2 expression is elevated in many cancers 
and activated immune cells like macrophages (Uebelhoer and Arispe 2016). Thus, PKM2 
is a key regulator of the Warburg effect in both cancer and immune cells. 
3.1 PKM2 and the Warburg Effect in ECs 
The Warburg effect is not limited to only cancer and proliferating cells but is also 
observed in both proliferating and non-proliferating endothelial cells. Like cancers cells, 
ECs preferentially use glycolysis for energy production with only 15% of ATP being 
generated from OX-PHOS (Culic et al., 1997; De Bock et al., 2013). Correspondingly, 
ECs have decreased mitochondrial usage with only 5% volume fraction consisting of 
mitochondria versus up to 30% volume fraction in other oxidative promoting cells (e.g. 
oxidative hepatocytes; Groschner et al., 2012). This preference for aerobic glycolysis is 
surprising since ECs are in immediate contact with high oxygen and glucose levels in 
blood, which are favorable for oxidative phosphorylation. However, the preferential use 
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of aerobic glycolysis in ECs is hypothesized to be advantageous, since glycolysis can: (1) 
help ECs conserve oxygen for perivascular tissue, (2) protect ECs from oxidative stress 
unlike oxidative phosphorylation which generates reactive oxygen species (ROS), (3) 
allow ECs to migrate into hypoxic tissues, (4) generate ATP more rapidly, and (5) 
facilitate quick adaptations for increased biomass production during angiogenesis 
(Verdegem et al., 2014; Uebelhoer and Arispe 2016). While all ECs preferential use of 
aerobic glycolysis, varied amounts of glycolysis is observed in different vascular beds. 
(Uebelhoer and Arispe 2016). For example, in comparison to quiescent ECs, angiogenic 
ECs have double rates of glycolysis generating 80% of ATP via glycolysis and less than 
1% of ATP via OX-PHOS (Culic et al., 1997; De Bock et al., 2013). 
PKM2 also plays a prominent role in ECs. PKM2 is the predominant isoform 
expressed in ECs and recent findings show PKM2 as a key regulator of angiogenesis. 
Exogenous circulating PKM2 induces endothelial cell proliferation, migration, and cell-
extracellular matrix adhesion leading to increased tumor angiogenesis and growth (Li et 
al., 2014). In the Arany lab, we have shown that deletion of PKM2 in endothelial cells 
results in decreased proliferation and migration (data unpublished). Both PKM1 and 
PKM2 expression are found in the cytosol, nucleus and lamellipodia extensions of ECs 
(Figure 2A-F, Data generated by Dr. Boa Kim). 
 
4. Mechanisms Regulating Endothelial Permeability 
4.1 VE-cadherin junctions   
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In ECs, pathways involved in mediating changes in permeability affect VE-
cadherin expression, function and organization (Gavard et al., 2014). Extracellularly, VE-
cadherin mediates cell-cell adhesion by clustering together at cell-cell contacts and 
adhering to VE-cadherins of adjacent endothelial cells. Intracellularly, VE-cadherin 
associates with several proteins (p120, β-catenin, and plakoglobin) to form a complex 
with α-catenin allowing for interaction with the actin-containing cytoskeleton (Dejana et 
al., 2008; Dejana and Vestweber, 2013). When permeability is induced in ECs, 
expression and function of VE-cadherin at cell-cell contacts are altered in several ways: 
(1) phosphorylation of phopho-tyrosine sites on the cytosolic tail of VE-cadherin (2) 
phosphorylation of other components in the VE-cadherin/catenin complex (3) by cleaving 
extracellular domains of the VE-cadherin (4) internalization of VE-cadherin/catenin 
complex (5) or mechanical stresses (Potter et al., 2005; Turoswki et al., 2008; Orsenigo et 
al., 2012).  
4.2 The Angiopoietin -Tie- Signaling Pathway  
The secreted, multimeric angiopoietin ligands regulate vascular homeostasis via 
the endothelial Tie receptor tyrosine kinases, Tie-1 and Tie-2 (Thurston and Daly, 2012). 
Angiopoietin-1 (Ang-1) functions in a paracrine and agonist manner, promoting vascular 
stabilizing effects via Tie-2 phosphorylation and activation. Ang-1 is mainly expressed 
by perivascular cells. Angiopoietin-2 (Ang-2) functions in an autocrine and antagonist 
manner by inhibiting the constitutively active Ang-1/Tie-2 signaling, promoting 
pathological angiogenesis, increased vascular permeability and inflammation. Ang-2 
inhibition of Tie-2 activity results in Rho-kinase and endothelial myosin light chain 
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kinase (EC-MLCK) activation, leading to destabilization of the endothelial monolayer 
(Maisonpierre et al., 1997; Parikh et al., 2006; Hakanpaa et al., 2015). In cells, Ang-2 is 
stored in intracellular granules called Weibel-Palade bodies (WBP) with a half-life of 
more than 18 hours (Fiedler et al., 2004). Ang-2 can be rapidly released from WPBs by 
activated endothelium. In humans and mice, Ang-2 expression is elevated during vessel 
remodeling of tumor endothelium and in vascular permeability associated pathologies 
like sepsis and acute lung injury (Parikh et al., 2006; Thurston and Daly, 2012).  
 
5. Preliminary Data  
A shotgun approach via RNA sequencing (RNA-Seq) of the whole transcriptome 
reveals reduction of Ang-2 mRNA expression upon overexpression of mouse PKM2 in 
endothelial cells (Figure 2G, Data generated by Dr. Boa Kim). Correspondingly, PKM2 
deletion in the endothelium induces Ang-2 mRNA expression (Figure 2H, Data generated 
by Dr. Boa Kim).  Ang-2 is a well-known modulator of vascular permeability. Thus, 
based on this preliminary data, we hypothesized that PKM2 deficient endothelium may 
exhibit a vascular permeability phenotype.  
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Figure 1 
Figure 1: Diagram of PKM2 structure, function (nuclear and glycolytic) and 
regulation. The tetramer formation of PKM2 promotes glycolysis and the generation 
of pyruvate, which can enter the TCA cycle for oxidative phosphorylation. The more 
active tetramer conformation of PKM2 is allosterically regulated by SAICAR, serine, 
FBP, or small-molecule activators. Without allosteric activators, the less active dimeric 
form of PKM2 predominates leading to accumulation of glycolytic intermediates that 
are shuttled into glycolytic branch pathways. Also, the dimeric PKM2 can translocate 
to the nucleus where it interacts with transcription factors (Hif-1α, STAT3, histone H3 
and JMJD5) to induce genes required for proliferation and glycolysis. PKM2 is 
dominantly expressed in cancer cells, activated or proliferating cells and endothelial 
cells (modified from Alves-Filho and Pålsson-McDermott, 2016). 
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Figure 2: PKM1 and PKM2 subcellular localization in endothelial cells and Ang-
2 mRNA expression in PKM2 deficient endothelium. Immunofluorescence staining 
of PKM1 (green, A-C) and PKM2 (green, D-F) reveals expression of both isoforms in 
the cytosol, nucleus and lamellipodia extensions. G, A shotgun approach via RNA 
sequencing (RNA-Seq) of the whole transcriptome in reveals reduction of Ang-2 
mRNA expression levels in human PKM2 deficient endothelium (si-27) that are 
overexpressing mouse PKM2 for 24hr and 48hrs (OE). H, Quantitative reverse 
transcription polymerase chain reaction analysis reveals induction of Ang-2 mRNA 
expression in PKM2 deficient endothelium.  
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METHODS 
Miles Assay 
Hair was shaved from the entire back of the mice one day prior to experiment. 
Mice were anesthetized with isoflurane and retro-orbitally injected with Evans blue dye 
(EBD, Sigma-Aldrich) at 50 mg/kg. After 10 minutes, recombinant human VEGF-A121 
or phosphate buffered saline (PBS) as a vehicle control was injected intradermally. After 
20 minutes, organs and skin were harvested and photographed. Tissues were incubated in 
1ml formamide at 56°C for 48 hours to extract extravasated dye. Absorbance of 
extravasated dye was measured at 620 nm with a standard curve of known dye 
concentrations and normalized to tissue weight.  
 
Cell Culture 
Human umbilical vein endothelial cells (HUVECs) and endothelial colony 
forming cells (ECFCs) were grown in endothelial basal medium (Lonza), supplemented 
with 10% FBS, 1% Pen/Strep and growth supplements (EGM-MV BulletKit, Lonza). All 
experiments with HUVECs were carried out between passage three and nine. All 
experiments with ECFCs were carried out between passage four and twenty.  
 
siRNA transfection 
HUVEC or ECFCs were seeded onto 0.1% gelatin-pretreated 10-cm or 6-cm 
plates. Cells were transfected with 10uM of siCTL (Sigma, SIC001), si-27 (Sigma, 
WDO5110433), si-87 (Sigma, WDO4615699), si-155 (Sigma, WDO4615697), si-Ang-2 
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(Sigma, WDO5975627), siPKM (Sigma, WDO5742340) in Opti-MEM (Fisher, cat no: 
31985-070) with Lipofectamine RNA iMAX (Invitrogen) for 6 hours. After 30-72 hours 
of transfection, cells were either fixed with 2% formalin for morphological examination 
or collected for mRNA, protein, or transendothelial electrical resistance (TER) analysis. 
 
Transendothelial Electrical Resistance (TER) Measurements  
Changes in transendothelial electrical resistance (TER) was measured in an 
endothelial monolayer using a 8-well gold microelectrode (8W10E+, 40 micro-electrodes 
per well, Applied Biosciences) pretreated with 10 mM L-cysteine and 1% gelatin. The 
8W1E+ electrode was connected to an electric cell-substrate impedance sensor (ECIS) 
system (Applied BioPhysics) in a chamber at 37°C with 5% CO2. Cells were reseeded 
from a 10cm plate to 8W1E+ electrode, 30 hours after transfection at a super confluent 
density of 250,000 per well. To measure endothelial permeability, resistance changes 
were measured for 14 hours at 4000Hz. Values from three to four wells were pooled and 
plotted as means ± SD.  
 
Quantitative real-time polymerase chain reaction (qPCR) assays 
Total RNA was isolated from cells using the TurboCapture 384 mRNA Kit 
(Qiagen, CA). RNA was reverse-transcribed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, CA). qPCR reactions were performed using the 
SYBR Green Master Mix and the CFX384 Real-Time System (Bio-Rad). All protocols 
were performed according to the manufacturers’ instructions. The qPCR data was 
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normalized to actin and calculated per the 2−ΔCt method. The list of genes investigated by 
qPCR and their respective primers are listed in Table 1.  
 
 
 
Immunostaining 
Cells were fixed in 2% neutral buffered formalin for 10 minutes and briefly 
permeabilized with 0.5% PBS-T for 5 minutes. Cells were rinsed three times in PBS for 1 
 15 
minute and blocked in Protein Block Serum-Free (Dako) for 1 hour. Cells were incubated 
with anti-goat VE-cadherin antibody (1:50, Santa Cruz, sc-8439) in a humidified 
chamber overnight at 4˚C. Cells were rinsed three times in PBS for 1 minute, and 
incubated with anti-phallodin 488 (1:200, Fisher) and donkey anti-goat Alexa fluor 594 
antibody (1:200, LifeTech, A11056) for 2 hours. Cells were rinsed three times in PBS for 
1 minute and mounted using Vectashield mounting medium (Vector Laboratories). Cells 
were examined using a Nikon Eclipse 80i microscope or an Olympus IX81 confocal 
microscope. All incubations were performed at room temperature unless otherwise noted.  
 
Westerns blots 
Cell lysates were collected using RIPA lysis buffer with protease and phosphatase 
inhibitors (Roche). Lysates was mixed with 6X SDS sample loading buffer (Bioworld), 
boiled for 5 minutes at 95 °C, and loaded onto 4–20% gradient Tris Glycine X-PAGE 
gels (Bio Rad). Separated proteins were wet transferred to a methanol activated PVDF 
membrane (Millipore). The membrane was blocked with 5% milk in TBS-T buffer for 1 
hour at room temperature and incubated with a primary antibody (1:5000) in 5% BSA in 
TBS-T buffer overnight at 4°C. The membrane was then washed and incubated with 
secondary HRP-linked antibody (1:10,000) in 5% milk in TBST buffer for 1 hour at room 
temperature. All washes were performed with TBS-T. Membranes were probed with the 
following antibodies: anti- Ang-2 (R&D systems, MAB0983-100), anti-phospho Y658-
VE-Cadherin (Thermo fisher, 44-1144G), anti-phospho Y685-VE-Cadherin (ECM 
Biosciences, CP1981), VE-CAD (Santa Cruz, sc-6458), pyruvate kinase M1 (Cell 
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signaling, 7067s), pyruvate kinase M2 (Cell signaling, 4053s), and actin (Cell signaling, 
4097s). The following HRP-line secondary antibodies were used: anti-mouse-HRP linked 
(Cell signaling, 7076s), anti-rabbit-HRP linked (Cell signaling, 7074s), or anti-goat-HRP 
linked (Thermo, 31400). The bands were visualized with a chemiluminescence detection 
kit (ECL, Amersham Biosciences) and imaged using (ImageQuant LAS 4000 series, GE 
Healthcare). 
 
Statistical Analysis. Data were expressed as means ± standard error of mean unless 
otherwise indicated. P values were calculated using the two-tailed Student's t-test or one-
way analysis of variance, followed by Bonferroni post hoc testing with p<0.05 as 
statistically significant. Data analysis and generation of all graphs were performed in 
PRISM5 software (Graphpad).  
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RESULTS 
Endothelial-specific PKM2 deletion in mice induces vessel permeability.  
To examine basal vascular permeability, Evans blue dye (EBD) was injected in 
control and PKM2 EC-specific KO mice, and various organs were assessed 30 minutes 
post injection. Compared to control mice, PKM2 EC-specific knockout (KO) mice 
exhibited increased extravasation of EBD into lung tissue (Figure 3A). No significant 
differences in EBD leakage were observed in kidney, liver and heart (Figure 3B-D) 
indicating that PKM2 deletion affects vessel permeability in an organ-specific manner. 
To examine acute vascular permeability, EBD was injected in control and PKM2 
KO mice and were subsequently injected intradermally with PBS and VEGF-A121.  
When compared with PBS, both control and PKM2 EC-specific KO mice exhibited 
increased extravasation of EBD vascular in response to VEGF-A121 (Figure 4A-B). But 
PKM2 EC-specific KO mice exhibited significantly more EBD extravasation than control 
mice in response to VEGF-A121 (Figure 4A-B), indicating that PKM2 EC-specific KO 
mice are more sensitive to VEGF-induced vascular permeability 
Endothelial-specific PKM2 deletion reduces endothelial monolayer integrity 
To evaluate whether PKM2 deletion in ECs alters endothelial barrier integrity, we 
measured transendothelial electrical resistance (TEER) using electrical cell impedance 
sensing (ECIS). Statistical analysis at a 14-hour end time point showed PKM2 deletion 
(si-27 and si-87) in human umbilical vein endothelial cells (HUVECs) significantly 
reduced TEER levels in the endothelial monolayers compared to control (Figure 5A-B). 
Interestingly, deletion of both PKM1 and PKM2 (si-PKM) did not alter TEER levels in 
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the endothelial monolayers compared to control (Figure 5A-B). Significant knockdown 
of both PKM1 (si-PKM) and PKM2 (si-27, si-87 and si-PKM) was verified via mRNA 
expression (Figure 5C-D). Upon knockdown of PKM2 with si-27, there is an induction of 
both mRNA (Figure 5D) and protein (Figure 7B) PKM1expression. This was not 
observed with the other PKM2 si-87 (Figure 5D).  
Endothelial-specific PKM2 deletion reduces VE-cadherin localization at cell-cell 
contacts 
To study the molecular organization of the adherent junctions that play an 
important role in maintaining endothelial barrier integrity, VE-cadherin localization was 
visualized by immunofluorescence. Endothelial colonizing forming cells (ECFCs) 
transfected with sRNA against PKM2 (si-27, si-155 and si-87) and a negative control 
scrambled sequence (si-CTL), were assessed at 1 hour, 4 hours, and 24 hours after 
reseeding and 48-72 hours after transfection. Knockdown of PKM1 (si-PKM) and PKM2 
(si-27, si-87 and si-PKM) was verified via mRNA expression (Figure 5C-D). Both 
control and PKM2 deficient endothelial cells show endogenous VE-cadherin expression 
in the perinuclear region 1 hour after of reseeding (Appendix A1). 4 hours after of 
reseeding, both control and PKM2 deficient endothelial cells began to exhibit VE-
cadherin localization at plasma membrane in regions where cell-to-cell contacts occur 
(Appendix A2). Highest expression of VE-cadherin was observed 24 hours after of 
reseeding in a confluent monolayer (Figure 6 and Appendix A3). VE-cadherin staining in 
confluent monolayer (Si-CTL) show continuous and narrow lining at cell-cell borders 
reflecting stable junctions (Figure 6A-C and Appendix A3, A-D). In PKM2 deficient 
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endothelial cells, VE-cadherin staining was discontinuous, a pattern typical for unstable 
junctions and the generation of intercellular gaps (Figure 6D-L and Appendix A3, E-P). 
Quantification of percent of cell membrane attached to adjacent cells revealed PKM2 
deficient endothelial cells have significantly less attachment to adjacent cells compared to 
control (Figure 6M).  
Interestingly, when PKM2 deficient endothelial cells are assayed without 
reseeding, VE-cadherin junctions are not disrupted (Appendix A4). Control cells show 
the characteristic differential pattern in VE-cadherin staining typically found in an 
endothelia monolayer (Appendix A4, A-C). In contrast, PKM2 deficient endothelial cells 
show a robust and uniform expression pattern of VE-cadherin (Appendix A4, D-I) 
indicating a loss in differential VE-cadherin expression pattern.  
Endothelial-specific PKM2 deletion induces phosphorylation of VE-cadherin at 
Y658  
Vessel permeability is accompanied by phosphorylation, disruption and 
internalization of VE-cadherin/catenin complex leading to weak cell–cell junctions. Thus, 
we evaluated both total VE-cadherin levels and phosphorylation of VE-cadherin at 
tyrosine residues 685 and 658. Deletion of PKM2 in ECs do not alter either total VE-
cadherin mRNA expression (Figure 7A) or total VE-cadherin protein levels (Figure 7B). 
But deletion of PKM2 in ECs increased VE-cadherin phosphorylation at tyrosine residues 
658 but not 685 compared to control (Figure 7B). Deletion of both PKM1 and PKM2 
deletion (si-PKM) decreased VE-cadherin phosphorylation at tyrosine residues 658 but 
not 685 compared to control (Figure 7B).  
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Endothelial-specific PKM2 deletion induces Ang-2 expression.  
The Ang-2 is a well-known modulator of vascular permeability. Based on our 
preliminary data of Ang-2 induction from qPCR and RNA-seq analysis, we further 
assessed Ang-2 expression in ECs. Compared to control, PKM2 deficient endothelium 
significantly induces Ang-2 mRNA expression with one of the PKM2 siRNAs (si-27 but 
not in si-87; Figure 8A). However, PKM2 deficient endothelium significantly induces 
Ang-2 protein expression with the both the PKM2 siRNAs (si-27 and si-87) compared to 
control (Figure 8B). Deletion of both PKM1 and PKM2 (si-PKM) reduced Ang-2 protein 
expression compared to control (Figure 8B).  
Loss of Ang-2 is sufficient to attenuate vascular leakage in PKM2 deficient 
endothelium 
We knocked down Ang-2 along with PKM2 to evaluate whether removal of Ang-2 
attenuated the effect of PKM2 deletion on leaky barrier function. Statistical analysis at 
14-hour end time point showed PKM2 deletion (si-87) in human umbilical vein 
endothelial cells (HUVECs) significantly reduced TEER of the endothelial monolayers 
compared to control (Figure 9A-B). Knockdown of Ang-2 (si-Ang-2) along with PKM2 
rescued TEER of the endothelial monolayers compared to control (Figure 9A-B). Thus, 
indicating that Ang-2 deletion is sufficient to attenuate vascular leakage in PKM2 
deficient endothelium. Knockdown of Ang-2 and PKM2 was verified via mRNA 
expression (Figure 9C-D). Similar to the preliminary data, PKM2 deficient endothelium 
induced Ang-2 mRNA expression (Figure 9D). Interestingly Ang-2 knockdown also 
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induces PKM2 expression (Figure 9C) suggesting that PKM2 and Ang-2 may 
reciprocally regulate each other.  
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Figure 3: Endothelial-specific PKM2 knockout mice show increased basal 
pulmonary microvascular permeability. Basal vascular permeability was assessed 
in various organs 30 minutes after retroorbital injection of EBD. A-D, Quantification 
of extracted EBD from lung (A), Kidney (B), liver (C), and heart (D). EBD values 
were normalized to tissue weight (μg of EBD/g of tissue). Only the lung from EC-
specific PKM2 KO mice showed significantly increased EBD leakage compared with 
control mice. Data are presented as mean± SEM. *P<0.05. n = 5 per experimental 
group.  
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Figure 4: Endothelial-specific PKM2 knockout mice are more sensitive to VEGF-
induced vascular permeability. Acute vascular hyperpermeability was assessed 
through miles assay. Mice were injected retro-orbitally with EBD and were 
subsequently injected intradermally with PBS and VEGF-121 (100ng). A, 
Representative skin images in response to PBS or VEGF-A121 intradermal injections. 
B, Quantification of extracted EBD normalized to tissue weight (μg of EBD/g of 
tissue). EC-specific PKM2 KO mice showed significantly increased leakage compared 
with control mice when treated with VEGF-A121. Data are representative of two 
independent experiments and are presented as mean± SEM. *P<0.05, ***P<0.001. n = 
10 per experimental group.  
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Figure 5: Loss of PKM2 expression results in decreased transendothelial 
electrical resistance (TEER). Human umbilical vein endothelial cells (HUVECs) 
were transfected with small interfering RNA (siRNA) targeted to PKM2 alone (si-27 
and si-87), to both PKM1+PKM2 (si-PKM) and to a scrambled sequence (si-CTL) as 
a negative control. A, Changes in electrical resistance in HUVEC monolayer were 
measured for 14 hours on an electric cell-substrate impedance sensor (ECIS) in 
8W1E+ plates at 4000Hz. Cells were reseeded from a 10cm plate to 8W1E+ plate 30 
hours after transfection. Data are presented as means ± SD (n = 3-4). B, End point 
electrical resistance was normalized to negative control group at 14 hours. EC-specific 
deletion of PKM2 (si-27 and si-87) results in decreased TEER. While EC-specific 
deletion of both PKM1 and PKM2 did not alter TEER. Data are presented as mean ± 
SEM (n = 3-4). ****P<0.0001. C and D, mRNA expression was assessed using 
quantitative reverse transcription polymerase chain reaction. There was significant 
knockdown of PKM1 (si-PKM) and PKM2 (si-27, si-87 and si-PKM) mRNA 
expression compared to control. mRNA expression was normalized to actin expression 
using the 2
−ΔCt
 method. Data are presented as mean ± SEM (n = 3). **P<0.01, 
***P<0.001 ****P<0.0001.  
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Figure 6: Loss of PKM2 expression results in disrupted VE-cadherin adherent 
junctions and gap formations. Endothelial colonizing forming cells (ECFCs) were 
transfected with small interfering RNA (siRNA) targeted to PKM2 (si-27, si-155, si-
87) and to a scrambled sequence (si-CTL) as a negative control. Cells were assessed 
24 hours after reseeding and 72 hours after transfection A-L, Representative images of 
a ECFC monolayer immunolabeled for VE-cadherin (Red), phalloidin (Green) and 
DAPI (Blue). In confluent endothelial cells, VE-cadherin staining was continuous, 
linear and distributed around the entire periphery of the cells reflecting stable 
junctions (A-C, arrow). In PKM2 deficient endothelial cells, VE-cadherin staining 
was discontinuous reflecting unstable junctions and formation of intercellular gaps (D-
L, open arrow head = discontinuous junctions and gap formations). M, Quantification 
of cell membrane (%) attached to adjacent cells. PKM2 deficient endothelial cells 
showed significantly less attachment to adjacent cells compared to control. Scale bars: 
50 μm. Data are presented as mean ± SEM (n = 3 random fields). ****P<0.0001. 
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Figure 7: PKM2 deficient endothelium induces VE-cadherin tyrosine 
phosphorylation at residues Y658. Human umbilical vein endothelial cells 
(HUVECs) were transfected with small interfering RNA (siRNA) targeted to PKM2 
alone (si-27 or si-87), both PKM1+PKM2 (si-PKM) and a scrambled sequence (si-
CTL) as a negative control. A, Quantitative analysis of total VE-Cadherin (VE-CAD) 
mRNA expression normalized to actin. Deletion of PKM2 in ECs do not alter VE-
cadherin mRNA expression. Data are presented as mean ± SEM (n = 3). B, Western 
blot analysis of phospho Y658-VE-Cadherin (p-VE-CAD-Y658), phospho Y685-VE-
Cadherin (p-VE-CAD-Y685), VE-CAD, pyruvate kinase M1 (PKM1), pyruvate 
kinase M2 (PKM2), and actin (as loading control). PKM2 deficient endothelium 
induces VE-cadherin tyrosine phosphorylation at Y658 without altering total VE-
cadherin protein levels. 
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Figure 8: PKM2 deficient endothelium induces Ang-2 expression. Human 
umbilical vein endothelial cells (HUVECs) were transfected with small interfering 
RNA (siRNA) targeted to PKM2 alone (si-27 and si-87), both PKM1+PKM2 (si-
PKM) and a scrambled sequence (si-CTL) as a negative control. A, Quantitative 
analysis of angiopoietin-2 (Ang-2) mRNA expression normalized to actin. Deletion of 
PKM2 in ECs induces Ang-2 mRNA expression. Data are presented as mean ± SEM 
(n = 3). ***P<0.001. B, Western blot analysis of Ang-2, pyruvate kinase M1 (PKM1), 
pyruvate kinase M2 (PKM2), and actin (as loading control). Deletion of PKM2 in ECs 
induces Ang-2 protein expression.  
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Figure 9: Knockdown of Ang-2 in PKM2-deficient cells is sufficient to rescue 
decreased transendothelial electrical resistance (TEER). Human umbilical vein 
endothelial cells (HUVECs) were transfected with small interfering RNA (siRNA) 
targeted to PKM2 (si-87), angiopoietin 2 (si-Ang-2) or a scrambled sequence (si-CTL) 
as a negative control. A, Changes in electrical resistance in HUVEC monolayer were 
measured for 14 hours on an electric cell-substrate impedance sensor (ECIS) in 
8W1E+ plates at 4000Hz. Cells were reseeded from a 10cm plate to 8W1E+ plate 30 
hours after transfection. Data are presented as means ± SD (n = 3-4). B, End point 
electrical resistance was normalized to negative control group at 14 hours. Loss of 
Ang-2 is sufficient to attenuate vascular leakage in PKM2 deficient endothelium. Data 
are presented as mean ± SEM (n = 3-4). ****P<0.0001. C-D, mRNA expression of 
PKM2 and angiopoietin 2 were assessed using RT-PCR. PKM2 deficient endothelium 
induces Ang-2 mRNA expression and interestingly Ang-2 knockdown also induces 
PKM2 expression. mRNA expression was normalized to actin expression using the 
2
−ΔCt
 method. Data are presented as mean ± SEM (n = 3). ***P<0.001, 
****P<0.0001.  
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DISCUSSION 
 Impairment in vessel stability and subsequent vascular permeability is the 
hallmark of many pathological diseases like cancer and sepsis. Thus, the control of the 
endothelial barrier function is essential for maintaining vascular homeostasis. Here we 
demonstrate using both in-vivo and in-vitro models, that pyruvate kinase M2 is required 
to preserve endothelial barrier function. 
Endothelial PKM2 deficient mice display increased basal vessel permeability in 
pulmonary capillary vessels, demonstrating that lung vascular permeability is regulated 
by PKM2. Due to its enormous surface area, the pulmonary vasculature is known to be 
particularly sensitive to barrier dysregulation (Xing and Birukova, et al. 2009). However, 
the kidney, heart and liver vasculature remained intact in EC-specific PKM2 deficient 
mice. Thus, PKM2 deletion affects vessel permeability in an organ-specific manner. This 
is not surprising as permeability of capillaries varies considerably from organ to organ 
due to their heterogenous morphologies and function (Aird et al., 2015). Also, endothelial 
PKM2 deficient mice display increased VEGF-induced acute vessel permeability in 
dermal vessels, suggesting that VEGF-induced vascular permeability is mediated by 
PKM2.  
Similar to in-vivo results, PKM2 deficient endothelium exhibited decreased 
transendothelial electrical resistance (TEER), indicative of reduced tightness of junctions 
in endothelial cell monolayer. PKM2 deficient endothelial cells have disrupted 
localization of VE-cadherin at the intercellular junctions and significantly less attachment 
to adjacent cells, but total VE-cadherin protein expression was conserved. This altered 
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VE-cadherin localization is consistent with the observed leaky phenotype given that 
previous studies have shown VE-cadherin adherent junctions play a crucial role in 
maintaining barrier integrity in ECs. Where loss of VE-cadherin at cell–cell contacts 
produces unstable junctions, intercellular gaps (Lampugnani et al., 2012) resulting in 
increased permeability.  
Modulation of VE-cadherin is mediated by several mechanisms one of which is 
by phosphorylation of VE-cadherin (Turowski et al., 2008). The cytoplasmic domain of 
VE-Cadherin has several phospho-tyrosine sites, but only three (Y658, Y685 and Y731) 
are involved in the regulation of barrier function (Adam, 2015). Thus, we evaluated 
phosphorylation of VE-cadherin at two of three tyrosine residues (Y685 and Y658). Loss 
of PKM2 in endothelial cells induces phosphorylation of VE-cadherin at residue Y658 
but not Y685.  Studies have shown phosphorylation at Y658, mediated by Src, has been 
implicated as a mechanism for loss of barrier function (Garrett et al., 2017). Specifically, 
phosphorylation at Y658 disrupts p120 binding to VE-cadherin, leading to internalization 
of VE-Cadherin. VEGF also is known to alter endothelial barrier function via 
phosphorylation of VE-Cadherin at residue Y658 (Potter et al., 2005; Gavard and 
Gutkind, 2006). Taken together, phosphorylation of VE-cadherin and the subsequent loss 
of VE-cadherin at cell-cell contacts suggests a mechanism by which PKM2 alters 
intercellular junctions leading to a leaky endothelium.  
Surprisingly, PKM2 deletion in an established endothelial monolayer (without 
reseeding) did not affect VE-cadherin localization at the cell-cell contacts. Instead, 
PKM2 deletion in an established endothelial monolayer led to a loss of differential VE-
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cadherin expression. Recent studies have linked loss of differential VE-cadherin 
junctional regulation to abnormal vascular phenotypes (Bentley et al., 2014).  
In this study, we observed a significant increase in the expression of Ang-2 
mRNA and protein in PKM2 deficient endothelium. The upregulation of Ang-2 mRNA 
and protein levels is consistent with the observed leaky phenotype given that previous 
studies have shown overexpression of Ang-2 leads to destabilization of vessels. Ang-2 is 
as an antagonist of the constitutively active Ang-1/Tie-2 signaling which participates in 
vessel stabilization (Maisonpierre et al., 1997; Fiedler et al., 2004). Specifically, Ang-2 
inhibits Tie-2 phosphorylation, resulting in Rho-kinase and endothelial myosin light 
chain kinase (EC-MLCK) activation and destabilization of the endothelial monolayer  
(Parikh et al., 2006). We also performed rescue experiments using TEER measurements 
to verify if leaky barrier function observed upon PKM2 deletion was specifically due to 
Ang-2 induction. Indeed, removal of Ang-2 was sufficient to attenuate the effect of 
PKM2 deletion on leaky barrier function. Therefore, in the endothelium PKM2 effects 
are mediated in part by altering Ang-2 expression. Furthermore, PKM2 and Ang-2 seem 
to reciprocally regulate each other, since knockdown of either PKM2 or Ang-2 induces 
mRNA expression of Ang-2 or PKM2, respectively.  
In PKM2 deficient endothelium, there is greater induction of PKM1 than in basal 
conditions. Thus, it is possible that PKM1 induction, rather than PKM2 loss, is mediating 
the leaky phenotype through VE-cadherin phosphorylation and Ang-2 induction. This 
matches our observation that upon double knockdown of PKM2 and PKM1, we see an 
intact vascular barrier function and concurrent reduction of VE-cadherin phosphorylation 
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and Ang-2 protein expression. In tumor cells a similar mechanism is observed, where 
PKM1 expression, rather than PKM2 loss, is responsible for proliferation arrest (Lunt et 
al., 2015). However, it is noted that we do not see a consistent induction of PKM1 among 
the different PKM2 siRNAs, but we do see a consistent induction in Ang-2 expression. 
Thus, it is not clear if PKM1 is indeed mediating the leaky phenotype. To resolve this 
question, looking at barrier function in PKM1 overexpressing ECs would elucidate if 
PKM1 expression, rather than PKM2 loss, is responsible for leaky vascular barrier.  
Conclusions 
Collectively, the data reported here suggests that pyruvate kinase M2 is required 
for maintaining vessel integrity and barrier function in endothelial cells. Specifically, the 
observed vascular leakiness of PKM2 deficient endothelium is mediated by increased 
Ang-2 expression and disrupted VE-cadherin junctions at cell-cell contacts. Recent 
studies have described the PKM2’s role in tumorigenesis and angiogenesis (Christofk et 
al., 2008; Azoitei et al., 2016), but this is the first study to describe PKM2’s role in 
barrier function. 
Future Directions 
Our results suggest that PKM2 regulates Ang-2 expression. However, it is unclear 
how and through which mechanism PKM2 mediates the leaky phenotypes via ANG-2 
modulation.   
PKM2 may alter other components of the angiopoietin-Tie-2 signaling axis and 
the downstream pathways. Ang-1/Tie-2 phosphorylation and activation leads to Rac1 
activation and RhoA inactivation, mediated by PI3K/Akt. Ultimately, increasing 
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accumulation VE-cadherin at the adherent junctions and preserving vascular barrier 
function (Milam and Parikh et al., 2015). By looking at protein activity of Tie-2, Rac1 
and RhoA, we clarify where PKM2 loss leads to changes in the angiopoietin-Tie-2 
signaling axis. Also, since Ang-1 is an agonist of the Tie-2 receptor and opposes the 
antagonistic action of Ang-2 (Maisonpierre et al., 1997; Fiedler et al., 2004), Ang-1 
treatment may possibly rescue the leaky phenotype of PKM2 deficient endothelium. 
Together this would further validate if and how PKM2 acts on the angiopoietin-Tie-2 
signaling axis.  
PKM2 may act more upstream by regulating both packaging and release of Ang-2 
from Weibel-Palade bodies (WBP). In lung microvascular endothelial cells, Ang-2 
release is regulated by the PTEN/PI3-kinase/Akt pathway. PTEN is a positive modulator 
of Ang-2 release, while activation of PI3-K/Akt pathway downregulates Ang-2 (Tsigkos 
et al., 2006; Parikh et al., 2006). By looking at protein activity of PTEN, PI3K and AKT, 
we can clarify if PKM2 loss alters both packaging and release of Ang-2. Studies have 
shown elevated serum Ang-2 levels elicit leaks in pulmonary endothelium of septic 
patients and mice (Hashimoto and Pittet, 2006, Parikh et al., 2006). Since we observe a 
similar leaky lung phenotype upon PKM2 deletion in mice, it would be valuable to assess 
if PKM2 deficient mice have a corresponding increase in circulating Ang-2. Thus, 
revealing if PKM2 deletion stimulates release of Ang-2 from WBP.  
Also, it is important to delineate the role of PKM2 in the context of a pathological 
disease like sepsis, which is associated with abnormally increased vascular permeability. 
Will PKM2 deletion in the endothelium sensitize the mice to septic shock? Or will 
 33 
overexpression of PKM1 or PKM2 mitigate and rescue the effects of septic shock? 
Ultimately, if PKM2 is relevant in sepsis or other permeability associated pathological 
diseases, regulation of PKM2 could open up possible new therapeutic targets.  
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Appendix A1: 1 hour after of reseeding, endogenous VE-cadherin expression 
localizes to the perinuclear region. Endothelial colonizing forming cells (ECFCs) 
were transfected with small interfering RNA (siRNA) targeted to PKM2 (si-27, si-
155, si-87) and to a scrambled sequence (si-CTL) as a negative control. Cells were 
assessed 1 hour after reseeding and 24 hours after transfection A-L, Representative 
images of a ECFC monolayer immunolabeled for VE-cadherin (Red), phalloidin 
(Green) and DAPI (Blue). Scale bars: 50 μm.  
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Appendix A2: 4 hours after of reseeding, VE-cadherin localizes at plasma 
membranes where cell-to-cell contacts occur. Endothelial colonizing forming cells 
(ECFCs) were transfected with small interfering RNA (siRNA) targeted to PKM2 (si-
27, si-155, si-87) and a scrambled sequence (si-CTL) as a negative control. Cells were 
assessed 4 hours after reseeding and 24 hours after transfection. A-L, Representative 
images of a ECFC monolayer immunolabeled for VE-cadherin (Red), phalloidin 
(Green) and DAPI (Blue). Arrow heads indicate VE-cadherin localization at plasma 
membranes. Scale bars: 50 μm.  
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Appendix A3: 24 hours after reseeding, loss of PKM2 expression results in 
disrupted VE-cadherin adherent junctions and gap formations. Endothelial 
colonizing forming cells (ECFCs) were transfected with small interfering RNA 
(siRNA) targeted to PKM2 (si-27) and a scrambled sequence (si-CTL) as a negative 
control. Cells were assessed 24 hours after reseeding and 72 hours after transfection 
A-P, Representative images of a ECFC monolayer immunolabeled for VE-cadherin 
(Red), phalloidin (Green) and DAPI (Blue). Confocal imaging of confluent 
endothelial cells show VE-cadherin staining as continuous, linear and distributed 
around the entire periphery of the cells reflecting stable junctions (A-H, arrow). In 
PKM2 deficient endothelial cells, VE-cadherin staining was discontinuous reflecting 
unstable junctions and formation of intercellular gaps (I-P, open arrow head = 
discontinuous junctions and gap formations). Scale bars: 40x = 50μm, 100x = 20μm.   
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Appendix A4: PKM2 deficient endothelium lack differential VE-cadherin 
expression. Endothelial colonizing forming cells (ECFCs) were transfected with small 
interfering RNA (siRNA) targeted to PKM2 (si-27 and si-87) and a scrambled 
sequence (si-CTL) as a negative control. Cells were assessed 48 hours after 
transfection with no reseeding. A-I, Representative images of a ECFC monolayer 
immunolabeled for VE-cadherin (Red), phalloidin (Green) and DAPI (Blue). Cells 
transfected with a si-CTL show the characteristic differential pattern in VE-cadherin 
staining in an endothelia monolayer (A-C). In contrast, PKM2 deficient endothelial 
cells show a robust and uniform expression pattern for VE-cadherin (D-I). Scale bars: 
50 μm.  
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